Jason N. Gorevic Sells 22,040 Shares of Teladoc Health, Inc. (NYSE:TDOC) Stock

Teladoc Health, Inc. (NYSE:TDOC – Get Rating) CEO Jason N. Gorevic sold 22,040 shares of the firm’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $25.91, for a total transaction of $571,056.40. Following the sale, the chief executive officer now owns 603,434 shares in the company, valued at approximately $15,634,974.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Teladoc Health Trading Down 0.6 %

Shares of NYSE:TDOC opened at $25.35 on Thursday. The company has a quick ratio of 3.15, a current ratio of 3.29 and a debt-to-equity ratio of 0.67. Teladoc Health, Inc. has a fifty-two week low of $21.60 and a fifty-two week high of $77.50. The firm has a 50-day simple moving average of $27.36 and a 200 day simple moving average of $27.85.

Teladoc Health (NYSE:TDOC – Get Rating) last announced its quarterly earnings data on Wednesday, February 22nd. The health services provider reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.04. Teladoc Health had a negative net margin of 567.53% and a negative return on equity of 4.35%. The business had revenue of $637.71 million during the quarter, compared to the consensus estimate of $633.71 million. On average, sell-side analysts predict that Teladoc Health, Inc. will post -1.39 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on TDOC. Oppenheimer decreased their price target on shares of Teladoc Health from $37.00 to $35.00 and set an “outperform” rating on the stock in a report on Thursday, February 23rd. SVB Leerink upgraded shares of Teladoc Health from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a report on Thursday, February 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price target on shares of Teladoc Health in a report on Thursday, February 23rd. SVB Securities upgraded shares of Teladoc Health from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a report on Thursday, February 23rd. Finally, StockNews.com upgraded shares of Teladoc Health to a “sell” rating in a report on Friday, February 24th. One equities research analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $34.84.

Institutional Investors Weigh In On Teladoc Health

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Teladoc Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 13,639,307 shares of the health services provider’s stock valued at $345,757,000 after buying an additional 78,859 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Teladoc Health by 879.2% during the 2nd quarter. Renaissance Technologies LLC now owns 4,475,319 shares of the health services provider’s stock valued at $148,625,000 after purchasing an additional 4,018,300 shares during the period. State of Michigan Retirement System boosted its stake in Teladoc Health by 1.2% during the 4th quarter. State of Michigan Retirement System now owns 3,783,000 shares of the health services provider’s stock valued at $89,468,000 after purchasing an additional 43,500 shares during the period. Geode Capital Management LLC boosted its stake in Teladoc Health by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,169,548 shares of the health services provider’s stock valued at $51,309,000 after purchasing an additional 72,396 shares during the period. Finally, Himension Capital Singapore PTE. LTD. boosted its stake in Teladoc Health by 67.7% during the 2nd quarter. Himension Capital Singapore PTE. LTD. now owns 2,167,552 shares of the health services provider’s stock valued at $71,984,000 after purchasing an additional 875,344 shares during the period. Institutional investors own 84.14% of the company’s stock.

About Teladoc Health

(Get Rating)

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.